N-Terminal Pro-B-Type Natriuretic Peptide

When high

When elevated (>125 ng/L at rest in males <50):

Immediate actions:

• Retest after 72 hours of complete rest to rule out exercise-induced transient elevation
• If persistently elevated: obtain echocardiogram (LV wall thickness, ejection fraction, diastolic function, global longitudinal strain)
• Check kidney function — reduced eGFR elevates NT-proBNP clearance time
• If >300 ng/L: cardiology referral is mandatory

Supplements (cardioprotective — do NOT replace medical evaluation):

• CoQ10 (Ubiquinol) -- 200-400mg/day: Improves mitochondrial energy production in cardiomyocytes, reduces oxidative stress
• Omega-3 (EPA/DHA) -- 4g/day: Anti-arrhythmic, anti-inflammatory, reduces blood pressure
• Magnesium (Taurate or Glycinate) -- 400-600mg/day: Antiarrhythmic, vasodilatory
• Taurine -- 3-5g/day: Cardioprotective, antiarrhythmic, reduces blood pressure

Lifestyle:

• Monitor blood pressure: target <130/80 mmHg — AAS-induced hypertension drives LVH
• Control haematocrit (<52%): high viscosity increases cardiac workload
• Regular cardiovascular exercise (150 min/week moderate-intensity)
• Consider annual echocardiography while using AAS
• If persistently >125 ng/L, strongly consider reducing to TRT doses
• Manage lipids aggressively

Pharmacological options (for confirmed cardiac strain or AAS-induced hypertension/LVH):

• Telmisartan -- 40-80mg/day; ARB; preferred for AAS users due to PPAR-gamma activity (improves lipids and insulin sensitivity); reduces cardiac afterload and slows LVH progression; also helps with elevated HCT
• Nebivolol -- 2.5-10mg/day; beta-1 selective beta-blocker with NO-mediated vasodilation; preferred over older beta-blockers in athletes (less impact on training capacity, no negative metabolic effects); excellent for AAS-induced hypertension and elevated resting heart rate
• ACE inhibitors (lisinopril, ramipril) -- equivalent cardiac protection to ARBs; cough is the main side effect; consider when telmisartan is unavailable
• Empagliflozin / Dapagliflozin (SGLT2 inhibitors) -- 10-25mg/day; increasingly used for HFrEF/HFpEF even without diabetes; renoprotective bonus
• Sacubitril/valsartan (Entresto) -- 49/51 to 97/103mg 2x/day; reserved for confirmed reduced-EF heart failure; cardiology-supervised
• Avoid non-selective beta-blockers (propranolol, atenolol) -- they impair training capacity and worsen lipid/insulin profiles in athletes
• Cardiology referral if NT-proBNP >450 pg/mL (men <50) or >900 (>50); any symptomatic elevation needs full workup including echo
• Reduce or discontinue offending AAS -- the most decisive intervention if cardiac strain is confirmed on echo; this is not optional in the setting of falling EF or progressive LVH
• All require physician oversight